Abstract
Background: Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non−immune checkpoint inhibitor (non-ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited. Methods: A comprehensive review was conducted on dermatologic toxicities associated with different classes of non-ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta-analyses; and case series/reports. Results: Dermatologic toxicities were associated with several types of non-ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non-ICI mAbs. Immunobullous reactions were rare and a subset of non-ICI mAbs were associated with the development of vitiligo cAEs. Conclusion: Dermatologic toxicities of non-ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non-ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.
Original language | English (US) |
---|---|
Pages (from-to) | 72-95 |
Number of pages | 24 |
Journal | Journal of cutaneous pathology |
Volume | 50 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2023 |
Keywords
- cutaneous adverse events
- dermatologic toxicities
- monoclonal antibodies
- oncologic dermatology
- targeted cancer therapy
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Dermatology